Literatura académica sobre el tema "FDA-approved drug"
Crea una cita precisa en los estilos APA, MLA, Chicago, Harvard y otros
Consulte las listas temáticas de artículos, libros, tesis, actas de conferencias y otras fuentes académicas sobre el tema "FDA-approved drug".
Junto a cada fuente en la lista de referencias hay un botón "Agregar a la bibliografía". Pulsa este botón, y generaremos automáticamente la referencia bibliográfica para la obra elegida en el estilo de cita que necesites: APA, MLA, Harvard, Vancouver, Chicago, etc.
También puede descargar el texto completo de la publicación académica en formato pdf y leer en línea su resumen siempre que esté disponible en los metadatos.
Artículos de revistas sobre el tema "FDA-approved drug"
Gould, Stephen J. "AIDS and FDA Drug-Approved Policy:". Journal of Health & Social Policy 2, n.º 2 (21 de febrero de 1991): 39–46. http://dx.doi.org/10.1300/j045v02n02_03.
Texto completoVokinger, Kerstin Noëlle y Aaron S. Kesselheim. "Application of orphan drug designation to cancer treatments (2008–2017): a comprehensive and comparative analysis of the USA and EU". BMJ Open 9, n.º 10 (octubre de 2019): e028634. http://dx.doi.org/10.1136/bmjopen-2018-028634.
Texto completoZhong, Hao, Ging Chan, Yuanjia Hu, Hao Hu y Defang Ouyang. "A Comprehensive Map of FDA-Approved Pharmaceutical Products". Pharmaceutics 10, n.º 4 (6 de diciembre de 2018): 263. http://dx.doi.org/10.3390/pharmaceutics10040263.
Texto completoEzeife, Doreen Anuli, Patricia Tang, Daniel Yick Chin Heng y Stephen Welch. "Comparison of drug approval between health Canada (HC) and the U.S. Food and Drug Administration (FDA)." Journal of Clinical Oncology 30, n.º 15_suppl (20 de mayo de 2012): 6082. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.6082.
Texto completoSaberian, Nafiseh, Azam Peyvandipour, Michele Donato, Sahar Ansari y Sorin Draghici. "A new computational drug repurposing method using established disease–drug pair knowledge". Bioinformatics 35, n.º 19 (6 de marzo de 2019): 3672–78. http://dx.doi.org/10.1093/bioinformatics/btz156.
Texto completoHershman, Dawn L., Alfred I. Neugut, Donna Buono, Catherine A. Richards, Sherry A. Glied y Jason Dennis Wright. "Off-label and compendia use of chemotherapy in patients with metastatic cancer." Journal of Clinical Oncology 31, n.º 15_suppl (20 de mayo de 2013): 6509. http://dx.doi.org/10.1200/jco.2013.31.15_suppl.6509.
Texto completoNair, Aathira Sujathan, Ashutosh Kumar Singh, Astik Kumar, Sunil Kumar, Sunitha Sukumaran, Vishal Payyalot Koyiparambath, Leena K. Pappachen, T. M. Rangarajan, Hoon Kim y Bijo Mathew. "FDA-Approved Trifluoromethyl Group-Containing Drugs: A Review of 20 Years". Processes 10, n.º 10 (11 de octubre de 2022): 2054. http://dx.doi.org/10.3390/pr10102054.
Texto completoKlasmeier, Coleen y Martin H. Redish. "Off-Label Prescription Advertising, the FDA and the First Amendment: A Study in the Values of Commercial Speech Protection". American Journal of Law & Medicine 37, n.º 2-3 (junio de 2011): 315–57. http://dx.doi.org/10.1177/009885881103700206.
Texto completoLosben, Nancy L. "2020: A Record Year for Drug Approvals". Senior Care Pharmacist 36, n.º 4 (1 de abril de 2021): 174–75. http://dx.doi.org/10.4140/tcp.n.2021.174.
Texto completoRizzo, Carla, Sara Amata, Ivana Pibiri, Andrea Pace, Silvestre Buscemi y Antonio Palumbo Piccionello. "FDA-Approved Fluorinated Heterocyclic Drugs from 2016 to 2022". International Journal of Molecular Sciences 24, n.º 9 (23 de abril de 2023): 7728. http://dx.doi.org/10.3390/ijms24097728.
Texto completoTesis sobre el tema "FDA-approved drug"
MASSARO, DAMIANO SERGIO. "Drug Reprofile for Friedreich’s Ataxia: Screening of an FDA-Approved Drugs Library searching for small molecules that increase Frataxin". Doctoral thesis, Università degli Studi di Roma "Tor Vergata", 2015. http://hdl.handle.net/2108/203080.
Texto completoCapua, Christopher James. "Comparative Cytotoxicity of an FDA-approved Cancer Drug to Extracts of Atriplex confertifolia on Human Breast and Cervical Cancer Cells". BYU ScholarsArchive, 2008. https://scholarsarchive.byu.edu/etd/1703.
Texto completoPéladeau, Christine. "Utrophin A Upregulation by FDA-Approved Drugs for the Treatment of Duchenne Muscular Dystrophy". Thesis, Université d'Ottawa / University of Ottawa, 2019. http://hdl.handle.net/10393/39298.
Texto completoAlqahtani, Saad Mohammed S. "Molecular Determinants for Binding of the FDA-Approved Drugs in Proteins – A Data Mining and Advanced Quantum Chemical Study". University of Toledo / OhioLINK, 2017. http://rave.ohiolink.edu/etdc/view?acc_num=toledo1493378726116385.
Texto completoFan, Ya-Wen y 范雅雯. "The effect and molecular action of curcumin in FDA-approved clinical drug-treated human bladder cancer cells". Thesis, 2014. http://ndltd.ncl.edu.tw/handle/63474138092702105330.
Texto completo國立臺灣師範大學
人類發展與家庭學系
102
Bladder cancer is the ninth most common cancer worldwide and the fourteenth most diagnosed malignancy in Taiwan (2013). Gemcitabine plus cisplatin (GC) treatment is prefered for nowadays treatment. For patients with impaired renal function, gemcitabine plus carboplatin (GCa) treatment is recommended. Overexpressions of Aurora A kinase and epidermal growth factor (EGF) were observed in bladder cancer cells. Our previously data demonstrate that curcumin significantly inhibited Aurora A gene expression, in part caused failure of various mitotic events and G2/M arrest of human bladder cancer cells. In this study, human bladder cancer T24 cells were treated with the existing chemotherapy (GC or GCa) in the presence and absence of curcumin. Addition of curcumin not only produced synergism using combination index analysis, but also raised the percentages of phases in sub-G1 (apoptosis rate) and G2/M using flow cytometry. Combinatio of cucurmin induced autophagy. Decreasing of phospho-Aurora A, p62, Beclin-1, phospho-PI3K, phospho-p70s6k, Atg12-Atg5 and increasing of LC3-II, phospho-mTOR, phospho-AKT, phospho-MEK, phospho-ERK were observed. Taken together, clinical drugs combined with curcumin not only inhibited activity of aurora a, but also promoted apoptosis and autophagy in T24 cells.
(8803004), Logan C. Ganzen. "Drug Screening Utilizing the Visual Motor Response of a Zebrafish Model of Retinitis Pigmentosa". Thesis, 2020.
Buscar texto completoChang, En-Kai y 張恩愷. "Combinatorial effects of six FDA approved drugs on influenza virus". Thesis, 2018. http://ndltd.ncl.edu.tw/handle/3272nt.
Texto completo國立陽明大學
微生物及免疫學研究所
106
英文摘要 Influenza virus belongs to Orthomyxoviridae. Influenza spreads around the world yearly, resulting in about three to five million cases of severe illness and about 250,000 to 500,000 deaths. The only drugs currently available to treat influenza are neuraminidase ( NA ) inhibitors,including oseltamivir ( Tamiflu ), zanamivir and peramivir, and an RNA-dependent RNA polymerase ( RdRp ) inhibitor, favipiravir ( Avigan ). Since influenza virus RdRp lacks proofreading activity, the genome is easy to mutate when replicating. As a result, drug resistance and limited vaccine protection occur. In this project, we hope to repurpose FDA-proved drugs for treating influenza. As to all viruses, influenza virus depends heavily on cellular mechanism to complete its life cycle. If inhibited cellular factors mediate the antiviral effects ( cellular factor-targeting ), drug-resistant influenza viruses may not be selected easily by cellular factor-targeting drugs as compared to virus-targeting drugs. Previously our lab used RdRp reporter assay to screen drugs, and found six drugs may inhibit influenza virus infection. All six drugs are generic drugs. Here I looked for combinations with synergistic anti-viral effects even at low drug dosages. A lower drug dosage will assert lower selection pressure on influenza virus and less cytotoxicity on host. In addition, treatment with multiple drugs decrease the possibility of drug-resistant viruses. First, the CC50 and IC50 of each of these six drugs were determind on MDCK and influenza-infected MDCK cells, respectively. Therapeutic index for each compound was calculated. Four out of six drugs tested were found to inhibit influenza virus replication by itself. Next, all of the binary and ternary combinations were tested, which concluded that a particular binary combination is most effective. In order to identify the likely steps suppressed by this combination, I added the drug combination at different time points post infection in time course assays and found that combination inhibited at early stage of the infection cycle. The results of hemagglutinin assay excluded that the combination inhibited HA protein binding to its receptor. Instead, the preliminary results supported that the combination acts on the step prior to viral RNP into cell nucleus. Testing the anti-viral ability of the combination on an animal model will further demonstrate its efficacy and potential in the future.
"Lead Identification, Optimization and Characterization of Novel Cancer Treatment Strategies Using Repositioned Drugs". Doctoral diss., 2013. http://hdl.handle.net/2286/R.I.18035.
Texto completoDissertation/Thesis
Ph.D. Chemical Engineering 2013
Wu, Chi-Shiuan y 吳奇軒. "The role of KRAS gene in combination treatment of Curcumin and FDA-approved Targeted Drugs in human colorectal cancer cells". Thesis, 2016. http://ndltd.ncl.edu.tw/handle/69752446398460271062.
Texto completoLibros sobre el tema "FDA-approved drug"
United States. Food and Drug Administration, ed. FDA Approved Animal Drug Products, 1998. [S.l: s.n., 1998.
Buscar texto completoUnited States. Food and Drug Administration. Office of Public Affairs., ed. FDA-approved bargain drugs: Generic products must meet high standards. 2a ed. Rockville, MD: Dept. of Health and Human Services, Food and Drug Administration, Office of Public Affairs, 2003.
Buscar texto completoR, Loughlin Kevin y Generali Joyce A, eds. The guide to off-label prescription drugs: New uses for FDA-approved prescription drugs. New York: Free Press, 2006.
Buscar texto completoMeridia: The weight-loss breakthrough : everything you need to know about the FDA-approved weight-loss pill. Rocklin, CA: Prima Health, 1998.
Buscar texto completoUnited States. Dept. of Defense. Office of the Secretary of Defense. y National Defense Research Institute (U.S.), eds. Military use of drugs not yet approved by the FDA for CW/BW defense: Lessons from the Gulf War. Santa Monica, CA: RAND, 1999.
Buscar texto completoCourtney, Charles H. Veterinary antiparasitic drugs 1991: A comprehensive compendium of FDA-approved antiparasitic drugs. Gainesville, Fla: Institute of Food and Agricultural Sciences, University of Florida, 1991.
Buscar texto completoUnited States. Food and Drug Administration. Office of Public Affairs., ed. FDA-approved bargain drugs: Generic products must meet high standards. 2a ed. Rockville, MD: Dept. of Health and Human Services, Food and Drug Administration, Office of Public Affairs, 2003.
Buscar texto completoUnited States. Food and Drug Administration. Office of Public Affairs., ed. FDA-approved bargain drugs: Generic products must meet high standards. 2a ed. Rockville, MD: Dept. of Health and Human Services, Food and Drug Administration, Office of Public Affairs, 2003.
Buscar texto completoUnited States. Food and Drug Administration. Office of Public Affairs, ed. FDA-approved bargain drugs: Generic products must meet high standards. 2a ed. Rockville, MD: Dept. of Health and Human Services, Food and Drug Administration, Office of Public Affairs, 2003.
Buscar texto completoUnited States. Food and Drug Administration. Office of Public Affairs., ed. FDA-approved bargain drugs: Generic products must meet high standards. 2a ed. Rockville, MD: Dept. of Health and Human Services, Food and Drug Administration, Office of Public Affairs, 2003.
Buscar texto completoCapítulos de libros sobre el tema "FDA-approved drug"
Rehman, Nahid y Anjana Pandey. "Nanomedicine Approved by FDA and EMEA". En Engineered Nanoparticles as Drug Delivery Systems, 79–90. Boca Raton: CRC Press, 2022. http://dx.doi.org/10.1201/9781003252122-8.
Texto completoHassan, Mubashir, Saba Shahzadi y Andrzej Kloczkowski. "Pharmacoinformatic Analysis of Drug Leads for Alzheimer’s Disease from FDA-Approved Dataset Through Drug Repositioning Studies". En Bioinformatics and Biomedical Engineering, 191–201. Cham: Springer Nature Switzerland, 2023. http://dx.doi.org/10.1007/978-3-031-34953-9_15.
Texto completoBarenholz, Yechezkel (Chezy). "Chapter 13. Doxil® – the First FDA-approved Nano-drug: from Basics via CMC, Cell Culture and Animal Studies to Clinical Use". En Drug Discovery, 315–45. Cambridge: Royal Society of Chemistry, 2016. http://dx.doi.org/10.1039/9781782622536-00315.
Texto completoMitra, Debanjan y Pradeep K. Das Mohapatra. "Computational Intelligence in Identification of Some FDA Approved Drug Compounds for Treatment of COVID-19". En Artificial Intelligence and Machine Learning Methods in COVID-19 and Related Health Diseases, 109–22. Cham: Springer International Publishing, 2022. http://dx.doi.org/10.1007/978-3-031-04597-4_5.
Texto completoGan, Julian, Jong Hyun Cho, Ryan Lee, Alireza Naghizadeh, Ling Yue Poon, Ethan Wang, Zachary Hui y Dongfang Liu. "Methods of Machine Learning-Based Chimeric Antigen Receptor Immunological Synapse Quality Quantification". En The Immune Synapse, 493–502. New York, NY: Springer US, 2023. http://dx.doi.org/10.1007/978-1-0716-3135-5_32.
Texto completoKim, Hahnsung, Yin Wu, Daisy Villano, Dario Livio Longo, Michael T. McMahon y Phillip Zhe Sun. "Analysis Protocol for the Quantification of Renal pH Using Chemical Exchange Saturation Transfer (CEST) MRI". En Methods in Molecular Biology, 667–88. New York, NY: Springer US, 2021. http://dx.doi.org/10.1007/978-1-0716-0978-1_40.
Texto completoScott, Kevin A. y Jon T. Njardarson. "Analysis of US FDA-Approved Drugs Containing Sulfur Atoms". En Sulfur Chemistry, 1–34. Cham: Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-030-25598-5_1.
Texto completoPéladeau, Christine y Bernard J. Jasmin. "Identifying FDA-Approved Drugs that Upregulate Utrophin A as a Therapeutic Strategy for Duchenne Muscular Dystrophy". En Methods in Molecular Biology, 495–510. New York, NY: Springer US, 2022. http://dx.doi.org/10.1007/978-1-0716-2772-3_26.
Texto completoLópez-Márquez, Arístides, Ainhoa Martínez-Pizarro, Belén Pérez, Eva Richard y Lourdes R. Desviat. "Modeling Splicing Variants Amenable to Antisense Therapy by Use of CRISPR-Cas9-Based Gene Editing in HepG2 Cells". En Methods in Molecular Biology, 167–84. New York, NY: Springer US, 2022. http://dx.doi.org/10.1007/978-1-0716-2010-6_10.
Texto completoAbou-el-Enein, Mohamed y Jordan Gauthier. "The Value of CAR-T-cell Immunotherapy in Cancer". En The EBMT/EHA CAR-T Cell Handbook, 231–34. Cham: Springer International Publishing, 2022. http://dx.doi.org/10.1007/978-3-030-94353-0_46.
Texto completoActas de conferencias sobre el tema "FDA-approved drug"
Raynal, Noël J., Justin T. Lee, Youjun Wang, Judith Garriga, Gabriel Malouf, Sarah Dumont, Elisha J. Dettman et al. "Abstract 380: Discovery of new epigenetic drugs among FDA-approved drug libraries". En Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA. American Association for Cancer Research, 2014. http://dx.doi.org/10.1158/1538-7445.am2014-380.
Texto completoGanapathy, Vadivel, Ellappan Babu, Sabarish Ramachandran y Yangzom D. Bhutia. "Abstract 1015: Repurposing the FDA-approved drug carbidopa to treat human cancers". En Proceedings: AACR 107th Annual Meeting 2016; April 16-20, 2016; New Orleans, LA. American Association for Cancer Research, 2016. http://dx.doi.org/10.1158/1538-7445.am2016-1015.
Texto completoTatman, Philip, Anthony Fringuello, Denise Damek, Samy Youssef, Randy Jensn, Kevin Lillehei y Michael Graner. "High-Throughput Drug Screening of FDA-Approved Cancer Drugs Reveals Novel Therapies for Patients with Chordomas". En 29th Annual Meeting North American Skull Base Society. Georg Thieme Verlag KG, 2019. http://dx.doi.org/10.1055/s-0039-1679578.
Texto completoGupta, Nancy Sanjay y Pravir Kumar. "TDP-43 Inhibitors in Amyotrophic Lateral Sclerosis: An Application of Drug Repurposing Approach Using FDA-Approved Drugs". En 2023 International Conference on Computational Intelligence and Sustainable Engineering Solutions (CISES). IEEE, 2023. http://dx.doi.org/10.1109/cises58720.2023.10183592.
Texto completoDing, Andy S., Joshua Casaos, Sakibul Huq, Henry Brem, Nicolas Skuli y Betty Tyler. "Abstract 2190: Repurposing the FDA-approved antiviral drug ribavirin as targeted therapy for nasopharyngeal carcinoma". En Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.sabcs18-2190.
Texto completoDing, Andy S., Joshua Casaos, Sakibul Huq, Henry Brem, Nicolas Skuli y Betty Tyler. "Abstract 2190: Repurposing the FDA-approved antiviral drug ribavirin as targeted therapy for nasopharyngeal carcinoma". En Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.am2019-2190.
Texto completoHuq, Sakibul, Joshua Casaos, Michael Peters, Yuanxuan Xia, Andy Ding, Manuel Morales, Noah Gorelick et al. "Abstract B06: Repositioning the FDA-approved antiviral drug ribavirin as targeted therapy for nasopharyngeal carcinoma". En Abstracts: AACR-AHNS Head and Neck Cancer Conference: Optimizing Survival and Quality of Life through Basic, Clinical, and Translational Research; April 29-30, 2019; Austin, TX. American Association for Cancer Research, 2020. http://dx.doi.org/10.1158/1557-3265.aacrahns19-b06.
Texto completoMitash, N., H. N. Alsafadi, R. H. Pineda, K. Kohler, M. Ishizuka, J. Sembrat, M. Lehmann, R. Chambers, D. E. Wagner y M. Koenigshoff. "Inhibition of YAP/TAZ Signaling by the FDA Approved Drug Verteporfin Attenuates Fibrosis in Mouse and Human Tissue". En American Thoracic Society 2022 International Conference, May 13-18, 2022 - San Francisco, CA. American Thoracic Society, 2022. http://dx.doi.org/10.1164/ajrccm-conference.2022.205.1_meetingabstracts.a5226.
Texto completoSenbabaoglu, Filiz, Ahmet Cingöz, Ezgi Kaya, Selena Kazancioglu, Nathan Alan Lack, Ceyda Acilan y Tugba Bagci-Onder. "Abstract B73: Screen among 1200 FDA-approved drug library reveals mitoxantrone as a TRAIL-sensitizing agent for glioblastoma multiforme". En Abstracts: AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; November 5-9, 2015; Boston, MA. American Association for Cancer Research, 2015. http://dx.doi.org/10.1158/1535-7163.targ-15-b73.
Texto completoSchultz, Christopher W., Teena Dhir, Samantha Z. Brown, Saswati Chand, Wei Jiang, Grace A. McCarthy, Alex O. Haber et al. "Abstract 3058: Recharacterizing the FDA approved drug pyrvinium pamoate as a clinically relevant HuR inhibitor in pancreatic ductal adenocarcinoma". En Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.am2019-3058.
Texto completoInformes sobre el tema "FDA-approved drug"
Matthews, Lisa, Guanming Wu, Robin Haw, Timothy Brunson, Nasim Sanati, Solomon Shorser, Deidre Beavers, Patrick Conley, Lincoln Stein y Peter D'Eustachio. Illuminating Dark Proteins using Reactome Pathways. Reactome, octubre de 2022. http://dx.doi.org/10.3180/poster/20221027matthews.
Texto completoScreening of ~5500 FDA-approved drugs and clinical candidates for anti-SARS-CoV-2 activity. EMBL-EBI, marzo de 2022. http://dx.doi.org/10.6019/chembl4651402.
Texto completo